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Objectives 
This methods report provides an 
overview of how medication data were 
collected and processed in the 2004 
National Nursing Home Survey (NNHS) 
and how analysts may use the 
medication data. The 2004 survey 
marked the first time that medication 
data were collected on sampled nursing 
home residents in the NNHS. 
Information about medications, which 
are an important component of nursing 
home care, can help policy makers, 
researchers, and members of the 
long-term care community better 
understand which medications are 
taken by U.S. nursing home residents. 
Methods 
The medication data were collected 
in the Prescribed Medications (PM) 
module of the 2004 NNHS. The 
computer-assisted personal interviewing 
(CAPI) instrument, which included a 
drug lookup list, allowed interviewers to 
enter a maximum of 25 medications 
taken on the day before the facility 
interview and a maximum of 25 
medications taken regularly but not on 
the day before the facility interview. 
This medication information, which is 
documented in residents’ medication 
administration records, was collected 
during a face-to-face interview at the 
nursing home facilities. All data were 
provided by facility respondents who 
used residents’ administrative and 
medical records to answer the survey 
items. The data were entered into the 
CAPI instrument that was loaded onto 
each interviewer’s computer laptop. 
Results and conclusions 
Data were collected on 13,507 
current residents, 98.5 percent of whom 
took one or more medications. A 
stand-alone PM Public-use File has 
been released. This file, which includes 
the sampling weight and design 
variables from the resident file, can be 
linked to the 2004 NNHS Current 
Resident Public-use File to generate 
national estimates on medications by 
various resident characteristics. 
Keywords: medications c National 
Nursing Home Survey c nursing 
homes c nursing home residents Collecting Medication Data in 
the 2004 National Nursing 
Home Survey 
by Lisa L. Dwyer, M.P.H., Division of Health Care Statistics Introduction
 
This methods report describes how 
medication data were collected in the 
2004 National Nursing Home Survey 
(NNHS). The NNHS has been 
conducted periodically since 1973 and 
was redesigned after the 1999 survey. 
Information on medications was 
collected for the first time in the 2004 
survey. The redesigned survey included 
the collection of many new data items, 
including medication information, 
because medications play a critical role 
in nursing home care. Many nursing 
home residents, the majority of whom 
are elderly and frail, take numerous 
medications to treat multiple chronic 
conditions. A 1991 study reported that 
‘‘the highest use of medications by 
Americans is in the institutionalized 
elderly’’ (1). Information about 
medications taken by nursing home 
residents is of great interest to policy 
makers, long-term care planners, and 
health services researchers, particularly 
as the U.S. elderly population continues 
to grow. Previous federal and nonfederal 
data collection initiatives have collected 
information on medication use in 
nursing homes. However, the results 
from these efforts are dated (e.g., 1996 
Medical Expenditures Panel Survey— 
Nursing Home Component) or not 
generalizeable to the entire U.S. nursing 
home population (e.g., Medicare Current 
Beneficiary Survey, National Medication 
Usage Survey, Systematic Assessment of 
Geriatric drug use via Epidemiology, 
and the Minimum Data Set). Medication 
data from the 2004 NNHS may be used to generate more current national 
estimates of medication use by U.S. 
nursing home residents. 
The National Nursing 
Home Survey (NNHS) 
The NNHS is one in a series of 
surveys that makes up the National 
Health Care Surveys (NHCS) conducted 
through the Division of Health Care 
Statistics (DHCS) by the Centers for 
Disease Control and Prevention’s 
National Center for Health Statistics 
(NCHS). The survey used a nationally 
representative sample of U.S. nursing 
home facilities to collect data on 
facilities’ staffing and services and on 
current residents (data on discharged 
residents were collected in previous 
survey years including 1999), including 
demographic information, health 
conditions, and services received. The 
redesign of the NNHS resulted in 
collecting medication data, as well as 
other new clinical survey items, for the 
first time in NNHS history. These data 
were collected in the Prescribed 
Medications (PM) module (see 
Appendix I). 
The 2004 NNHS medication data 
are available online in a public-use file. 
The file includes the name and 
characteristics of medications taken by 
sampled nursing home residents. The 
data can be linked to the Current 
Resident Public-use File, which includes 
residents’ demographic, health status, 
and payment information and 
information on services received. Page 1 
Page 2 [ Series 1, No. 47 Information on medication dosage, 
strength, frequency, and route was not 
collected in this survey. The data from 
the 2004 NNHS are the most recent 
nationally representative data available 
on medications taken by nursing home 
residents. 
Sample Design 
The 2004 NNHS used a sampling 
frame of U.S. nursing homes drawn 
from the Centers for Medicare & 
Medicaid Services’ Provider of Services 
file of U.S. nursing homes and state 
licensing lists compiled by SMG 
Marketing Group. The combined files 
were matched and unduplicated, 
resulting in a sampling frame of 16,628 
nursing homes. 
Sampling for the NNHS used a 
stratified two-stage probability design. 
The first stage was the selection of 
facilities and the second stage was the 
selection of residents. The primary strata 
of facilities were defined by bed size 
category and metropolitan statistical area 
status. Within primary strata, facilities 
were sorted by the following factors: 
certification status; hospital-based 
compared with nonhospital based status; 
ownership; geographic region; and state, 
county, and ZIP Code. Nursing homes 
were then selected using systematic 
sampling with probability proportional 
to bed size. For the 2004 NNHS, 1,500 
nursing homes were selected to 
participate. 
The second-stage sampling of 
current residents was carried out by the 
interviewers using a programmed 
algorithm in their laptops when they 
visited the facilities to conduct the 
interview. The sampling frame for 
current residents was the total number 
of residents on the facility rolls as of 
midnight on the day before the survey 
interview. Residents who were 
physically absent from the facility 
because of an overnight leave or a 
hospital visit, but had a bed maintained 
for them at the facility, were included in 
the sampling frame. A sample of up to 
12 current residents per facility was 
selected. Pretest
 
The 2004 NNHS pretest was 
administered in 75 nursing homes in 
June and July 2003. The pretest allowed 
NCHS to gain direct experience with the 
PM module under normal interviewing 
conditions (2). Interviewers did not 
report any major problems in retrieving 
medication information from the 
residents’ medication administration 
records (MARs) during the pretest. 
Some respondents retrieved the MARs 
from the nurses’ stations to answer 
medication questions. In other cases, 
because the medication questions were 
mentioned in the Key Items for Data 
Collection (see Appendix II) sent to 
appointed facilities in the confirmation 
package prior to the interview, some 
nursing facilities included the MARs in 
the residents’ charts, which facilitated 
collecting these data. 
The main problem with using the 
MARs was in collecting data on the 
reason why the medication was 
prescribed, which is typically found with 
the drug order. For these cases, the 
interviewers were trained to enter ‘‘don’t 
know.’’ However, some conscientious 
respondents looked up information in 
the Drug Handbook, called other 
coworkers for drug classification 
information, or answered using their 
existing knowledge of the medication 
indication. These extra efforts increased 
administration time and were not 
performed by all respondents. This 
contributed to the inconsistent collection 
of this information, which ultimately 
was not released in the public-use file. 
National Response 
Rates 
Of the 1,500 nursing home facilities 
selected to participate in the national 
survey, 283 refused to participate and 43 
were considered out of scope for one or 
more of the following reasons: the 
nursing home had gone out of business, 
it failed to meet the minimum definition 
(i.e., a facility or unit licensed as a 
nursing home or a nursing facility by 
the state health department or some other state agency and a facility that has 
three or more beds) used in this survey, 
or it was a duplicate of another facility 
in the sample. A total of 1,174 nursing 
homes participated at the first stage by 
providing facility information, resulting 
in a first-stage response rate of 81%. A 
total of 14,017 residents were sampled 
from the responding facilities. Of these 
residents, 8 were out of scope and for 
502 residents the facilities refused to 
provide resident information or ran out 
of time. This yielded a second-stage 
response rate of 96%. The overall 
response rate for the resident component 
of the 2004 NNHS was 78%. Complete 
information was collected on 13,507 
residents. 
The National 
Ambulatory Medical 
Care Survey 
(NAMCS) Drug 
Database 
The 2004 NNHS medication data 
were collected using the National 
Ambulatory Medical Care Survey 
(NAMCS) drug database. The NAMCS 
is another survey within the family of 
National Health Care Surveys. NAMCS 
has a drug database to code and 
adjudicate the medication names 
collected in its survey. The 2004 NNHS 
used a lookup list of medications 
constructed from the NAMCS drug 
database during the pilot and pretest 
phases of the survey. The lookup list 
contained the names of 908 medications 
most frequently prescribed for nursing 
home residents; these medications were 
compiled from conditions most 
commonly reported by physicians of 
elderly patients in the NAMCS and by 
facility respondents in the Medicare 
Current Beneficiary Survey’s long-term 
care facility component. Modeling the 
collection and coding of NNHS 
medication data after the NAMCS will 
allow NCHS to compare medications 
taken by elderly populations across 
different providers surveyed in the 
NHCS–nursing homes, physician 
offices, hospital outpatient facilities, and 
hospital emergency rooms. 
Series 1, No. 47 [ Page 3 Approximately 89.8% of the 
medications reported in the survey were 
in the 2004 NNHS CAPI lookup list. 
The NAMCS drug database, which 
holds information on more than 11,000 
medications (prescription and 
over-the-counter (OTC) drugs) and their 
characteristics, can be accessed at 
http://www.cdc.gov/nchs/about/major/ 
ahcd/ambulatory.htm. 
Drug Characteristics 
The NAMCS drug database 
contains the following six characteristics 
for each medication: 
1.	 Generic name code: A unique 
five-digit code for the chemical 
name of a drug (3). 
2.	 Rx status code: A code that indicates 
whether the medication is available 
by prescription (Rx) only or as an 
OTC drug in the noninstitutionalized 
setting. In the nursing home setting, 
all medications given to a nursing 
home resident—even OTCs, 
including vitamin, mineral, or herbal 
supplements—must be ordered by a 
physician and, therefore, are 
considered prescriptions. Despite 
this, the NAMCS drug database 
contains information on how the 
medication is available in the 
noninstitutionalized setting: 
+	 1 = Prescription. 
+	 2 = OTC (over the counter). 
+	 3 = Undetermined. 
+	 4 = Illicit (although there are 
some illicit drugs in the 
NAMCS drug database, none 
were reported in the 2004 
NNHS.) 
3.	 Drug Enforcement Agency (DEA) 
status code: A code that describes 
the abuse potential of the medication 
(i.e., is a person more likely to 
become addicted to the medication) 
from least controlled to most 
controlled: 
+	 1 = Schedule I (research only); 
high abuse potential. 
+	 2 = Schedule II (high abuse 
potential; abuse may lead to 
severe psychological or physical 
dependence). +	 3 = Schedule III (lower abuse 
potential). 
+	 4 = Schedule IV (low abuse 
potential; abuse may lead to 
limited physical or psychological 
dependence). 
+	 5 = Schedule V (lowest abuse 
potential). 
+	 6 = Uncontrolled. 
4.	 Composition (Comp) status code: A 
code that indicates the drug makeup 
as a single entity or combination 
product: 
+	 1 = Single entity drug. 
+	 2 = Combination drug. 
+	 3 = Undetermined. 
5.	 Ingredient code: A unique five-digit 
code for the active ingredient in a 
medication. An active ingredient is 
any component of a drug product 
intended to furnish pharmacological 
activity or other direct effect in the 
diagnosis, cure, mitigation, 
treatment, or prevention of disease, 
or to affect the structure or any 
function of the body of humans or 
animals (4). The NAMCS drug 
database can hold up to five active 
ingredients for each medication. 
6.	 Drug class code: A four-digit code 
that describes the therapeutic effect 
of the medication based on the organ 
or system on which the medication 
acts and its chemical, 
pharmacological, and therapeutic 
properties (5). The NAMCS drug 
database allows up to three 
therapeutic classes per medication, 
although the majority of medications 
belong to only one or two 
therapeutic classes. The therapeutic 
classification system used to code 
new medications in the 2004 NNHS 
is the 1995 National Drug Code 
(NDC) Directory (see Appendix III), 
which was the most current version 
at the time of the survey. 
Data Collection 
The 2004 National Nursing Home 
Survey was conducted from August 
2004 through January 2005. The survey 
consisted of two facility modules (the Facility Qualifications module and the 
Facility Characteristics module), two 
sampling modules (for residents and 
nursing assistants), and four resident-
level modules. The Prescribed 
Medications (PM) module that collected 
the medication data was one of the four 
resident-level modules. 
In the PM module, the following 
questions were asked about each 
sampled resident: What medications 
were taken by the resident during the 24 
hours of the day before the facility 
interview, including standing or routine 
medications or PRN (i.e., as needed) 
medications? (question PM1A); and 
What medications were taken regularly 
by the resident but not during the 24 
hours of the day before the facility 
interview, including standing orders for 
administration only, but excluding PRN 
medications (question PM2A)? The drug 
lookup list was used to enter responses 
to these two questions. The type of 
medication order (i.e., standing, routine, 
or PRN) for each medication was not 
collected; nor was dosage, strength, 
route, or frequency information 
collected. 
The survey included these two 
separate medication questions because 
some medications are administered 
weekly or even monthly, as in the case 
of some osteoporosis drugs (e.g., 
alendronate) or commonly prescribed 
supplements (e.g., vitamin B-12). 
Therefore, the survey instrument was 
designed to capture information on 
medications taken every day through 
question PM1A and on medications 
taken regularly but not every day 
through question PM2A. The medication 
data provided by the facility respondent 
were collected as brand or generic 
name, whichever the facility respondent 
provided. The facility respondent, who 
was familiar with the residents and their 
care, was selected by the nursing home 
administrator to answer the data items in 
the resident-level modules. 
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Was Prescribed and 
Adverse Events 
For each medication collected in the 
2004 NNHS, information was collected 
on the reason the medication was 
prescribed and the adverse events 
experienced by the resident. These data 
were entered manually by the 
interviewer; they were not collected 
using a lookup list. After the data 
collection period ended, a corresponding 
International Classification of Diseases, 
9th Revision, Clinically Modified 
(ICD–9–CM) code was assigned to each 
‘‘Reason why prescribed’’ entry, using a 
computerized matching algorithm. 
Because these data were not collected 
consistently, they were not included in 
the Prescribed Medications Public-use 
File (PM PUF). As mentioned 
previously, interviewers as well as 
observers of select interviews found 
that, in many cases, the reason why the 
medication was prescribed was not 
documented in the MARs and was 
reported inconsistently across 
respondents. 
Data on adverse events were also 
collected for each medication reported 
in the 2004 NNHS. Medication errors 
and adverse events are prevalent in the 
U.S. health care system (6). However, 
because the number of adverse events 
reported in the NNHS was very low 
(less than 1% of all nursing home 
residents), cell sizes are small and 
estimates are unreliable, particularly if 
the data are analyzed by basic 
demographic variables (e.g., sex and 
age). As a result, NCHS omitted this 
information from the PM PUF. 
Data Processing 
Medication names that field 
interviewers did not find in the drug 
lookup list at the time of interview were 
entered manually into the ‘‘Other, 
specify’’ field as text strings. These text 
strings were compiled into drug batches 
and later reviewed by the coding staff, 
who determined if the text strings could 
be back-coded to a pre-existing drug name. If an exact match was found for 
the text string, then it was coded 
accordingly. If not, the coders searched 
for the medication name (i.e., text 
string) using various pharmacy 
references and documented any 
information found. 
The next level of review was 
conducted by a pharmacist who 
reviewed the coders’ decisions and 
coders’ notes and attempted to assign 
codes to uncodeable medications. The 
pharmacist was able to override the 
coders’ initial decisions when 
appropriate. The pharmacist also added 
decision notes, particularly related to 
medications’ active ingredients. All 
medication text strings that were still 
uncodeable after review by the coders 
and the pharmacist were sent to NCHS 
for review and adjudication. 
Adjudication included the review of 
the medication name entered into the 
CAPI, the drug name code assigned by 
the coders (and second drug name code 
if there was a discrepancy between the 
two coders’ assignments), the coders’ 
notes, the ‘‘Reason why prescribed’’ 
field, and the pharmacist’s notes. In 
adjudication, NCHS researched a 
medication name and its characteristics 
(i.e., generic name, active ingredients, 
composition status, DEA status, and 
therapeutic class) to determine if it was 
a valid drug. This research involved 
using a combination of pharmacology 
references and clinical staff or contacts 
who were familiar with medications 
commonly used in nursing homes. If 
NCHS was able to confirm that the 
medication was a valid drug, the drug 
information was entered into the 
NAMCS drug database, which 
automatically assigned the medication a 
unique five-digit drug name code. The 
drug name code has a two-digit prefix 
that corresponds to the year of data 
collection, followed by three digits— 
starting with 001—that are assigned in 
sequential order. Medications that were 
still ‘‘uncodeable’’ even after NCHS 
review were coded as 99980. These 
uncodeables resulted from incorrect 
spelling or data entry (e.g., in a few 
cases, the names of medical devices or 
manufacturer names were entered). In 
all, 6,186 unique drug entries were coded. A total of 272 medications were 
added to the NAMCS drug database; the 
majority of them were vitamin or 
mineral supplements. 
File Edits 
The majority of edits for the 
medication data were for the ‘‘Reason 
why prescribed’’ item. Because these 
data were entered manually by 
interviewers, there were varied spellings 
for many medical conditions. The 
ICD–9–CM was used to code the 
diagnoses and medical conditions. The 
coding entailed two steps, combining 
the efforts of interviewers and trained 
medical coders: unique conditions in 
earlier batches were matched to similar 
conditions in later batches to provide 
suggested codes, and exact matching to 
medical coding text-to-code tables from 
the field test and other in-house projects 
was used to provide suggested codes. 
The coders reviewed the suggested 
codes and the various spellings for 
reported medical conditions, combining 
the suggested codes into a ‘‘best’’ 
suggested code where possible. This 
coding was then thoroughly reviewed 
and finalized by the medical coders, 
who were trained certified nosologists. 
Three major coding issues were 
identified for the ‘‘Reason why 
prescribed’’ survey item: 
1. Inconsistent data entries. 
2. Nondescript entries. 
3. Dual coding. 
Although this survey item was designed 
to collect information about medical 
conditions, it was found that dosage 
information (e.g., ‘‘bid’’ for twice daily), 
symptoms, and ICD–9–CM codes were 
reported as well. In other cases, the data 
entered were extremely vague or 
nondescript, forcing the coder to guess 
the field interviewer’s entry or to leave 
the corresponding ICD–9–CM field 
uncoded; examples include ‘‘SUPP,’’ 
‘‘Mental,’’ ‘‘Blood,’’ and 
‘‘Maintenance,’’ to name some. Finally, 
dual coding caused the most concern. In 
some cases, the ‘‘Reason why 
prescribed’’ field contained two 
conditions, such as ‘‘MI/CAD’’ for 
myocardial infarction 
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resulted in assigning two ICD–9 codes 
for dual conditions. Ideally, the field 
interviewer would have asked the 
respondent to provide the primary 
reason for why a medication was taken 
and then code that single condition. An 
NCHS in-house medical coder reviewed 
the dual coding cases and provided 
direction in editing these fields. Even 
after expending these resources for file 
edits, NCHS decided not to release the 
‘‘Reason why prescribed’’ data in the 
PM PUF as these data failed to meet 
data quality standards. These data are 
available upon request through the 
NCHS Research Data Center. 
Disclosure Risk 
Review 
Under Section 308(d) of the Public 
Health Service Act (42 U.S.C. 242m), 
the confidentiality of sampled 
establishments, providers, and patients 
in NCHS surveys is protected. As a 
result, all public-use files released by 
NCHS must complete the disclosure risk 
review process to protect the facilities 
and patients for whom data were 
collected from being identified. NCHS 
staff reviewed the 2004 NNHS 
medication data along with other 
resident data to ensure that no drug 
information could inadvertently disclose 
the identity of a nursing home or any of 
its residents. 
Prescribed 
Medications 
Public-use File (PM 
PUF) 
The PM PUF is a stand-alone file 
of 13,507 records. The file was designed 
to make it easier for analysts to 
manipulate the data. If the residents’ 
medication information were included in 
the Current Resident Public-use File, the 
file would have been too large, requiring 
a great deal of computer memory; 
therefore, the PM PUF is a separate file that can be linked 
to the Current Resident Public-use File 
when it is necessary to examine other 
resident variables. 
Each record in the PM PUF 
represents a sampled resident who has a 
unique resident identification number 
(RESNUM) that can be linked to its 
counterpart in the Current Resident 
Public-use File. The RESNUM is 
randomly generated and assigned to a 
unique resident. The remaining variables 
in the PM PUF are for the 25 
medications taken during the 24 hours 
of the day before the facility interview 
(i.e., PMCODE01–PMCODE25), the 15 
medications taken regularly but not 
during the 24 hours of the day before 
the facility interview (i.e., OTHPMC01– 
OTHPMC15), the drug characteristics 
for each medication, the survey design 
variables, and the sample weights that 
are necessary to generate accurate 
national estimates of medication use. 
Additional information on design 
variables and sample weights is found in 
the following text. Each medication is 
identified by a unique five-digit drug 
code (unless the medication was 
uncodeable, in which case it remains 
coded as 99980). The drug 
characteristics provide further 
information about the medications as 
described in the previous Drug 
Characteristics section. 
The PM PUF can be used to 
generate national estimates of medication 
use, such as the mean number of 
medications per resident. Other analyses 
that examine specific drugs or 
therapeutic classes can also be 
conducted by creating a subset of 
resident records with the corresponding 
drug name codes or therapeutic class 
codes and linking these records to the 
Current Resident Public-use File; this 
process facilitates creating a more 
manageable analytic file. The Current 
Resident Public-use File contains 
information on residents’ demographics, 
health status, services used, and sources 
of payment. The SAS and ASCII 
versions of the PM PUF may be 
accessed at ftp://ftp.cdc.gov/pub/ 
Health_Statistics/NCHS/Datasets/NNHS/ 
nnhs04/. Separate SAS, SPSS, and 
STATA input statements and variable 
label statements are also available at this website. The data dictionary for the PM 
PUF is available at http://www.cdc.gov/ 
nchs/data/nnhsd/March07_ 
WebPMfiledatadictionary.pdf. The data 
dictionary provides the file layout with 
the variable names, file positions, field 
descriptions, formats (character or 
numeric), lengths, and values. The 
frequencies for responses to select 
variables in the PM PUF may be 
verified on pages 33–36 of the PM PUF 
data dictionary. The data dictionary for 
the Current Resident Public-use File 
may be accessed at ftp://ftp.cdc.gov/pub/ 
Health_Statistics/NCHS/Dataset_ 
Documentation/NNHS/nnhs04/ 
2004ResidentFile_DataDictionary_ 
021607.pdf. 
Recodes 
Four additional variables were 
created from the original medication 
data and were added to the PM PUF: 
ANYMEDS, RXMED, RXOTH, and 
RXTOT. ANYMEDS shows if the 
nursing home resident took any 
medications. The overwhelming majority 
of residents, 99%, took at least one 
medication. RXMED provides the total 
number of medications taken by the 
resident during the 24 hours of the day 
before the facility interview; the range is 
0 to 25. RXOTH shows the number of 
medications a resident took regularly but 
not during the 24 hours of the day 
before the facility interview; the range is 
0 to 15. Although the CAPI instrument 
was designed to collect up to 25 
medications taken regularly but not 
during the 24 hours of the day before 
the facility interview for each resident, a 
maximum of 15 medications were 
reported for this item (i.e., no resident 
took more than 15 medications regularly 
but not on the day before the facility 
interview). RXTOT is the sum of 
RXMED + RXOTH; the range is 0 to 
30. 
Design Variables 
The PM PUF and the other NNHS 
public-use files include design variables 
that designate each record’s stratum 
marker and the first-stage unit (or 
cluster) to which the record belongs. 
These design variables must be used in 
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 statistical software programs to obtain 
accurate variances of the survey 
estimates. Design variables compute the 
inter- and intra- cluster variances and 
adjust for the complex survey design. 
Survey Weighting 
Procedures 
Because the NNHS is designed to 
produce unbiased national estimates for 
medications taken by nursing home 
residents, the data must have weights to 
inflate the numbers of sampled residents 
and their medications that would result 
if all U.S. nursing home residents were 
sampled; therefore, each record on the 
data file is assigned a weight. By 
aggregating these weights, counts can be
obtained for nationally representative 
data. The weight is constructed to reflect
the design of the sample: a stratified 
multistage, probability proportional to 
size, systematic design. The following 
are components of the sample weight: 
Inverse of the probability of 
selecting the nursing home 
resident 
The probability of selecting a 
nursing home resident is a product of 
the two selection probabilities: the 
probability of selecting a facility in the 
NNHS sample and the probability of 
selecting the nursing home resident 
within the sampled NNHS facility. The 
inverse of the product of these 
probabilities is used in weighting. 
Adjustment for nonresponse 
The second component for 
calculating the weight is adjustment for Table A. Computations using SUDAAN 
File 
Prescribed medications file . . . . . . .  
P
D
Table B. Computations using STATA 
File 
Prescribed medications file . . . . . . .  nonresponse. There are three types of 
nonresponse. The first two types are 
facility level and the third is person 
level. The first type occurs when 
in-scope facilities do not respond to the 
NNHS. The second type occurs when an 
in-scope facility does not provide the 
number of nursing home residents 
within the facility. The third type occurs 
when the administrative and medical 
records of the sampled residents are not 
made available to complete the survey. 
Ratio adjustment and weight 
smoothing 
The final components of calculating 
weights involve ratio adjustment and 
smoothing. Ratio adjustments are made 
within each of the groups defined by 
region to adjust for over- or under-
sampling of facilities reported in the 
sampling frame. This adjustment is a 
multiplicative factor whose numerator 
was the number of nursing home 
facilities in the sampling frame within 
each region and whose denominator was 
the estimated number of nursing home 
facilities for that same group. Ratio-
adjusted weights are smoothed only if 
there are disproportionately large 
weights. In smoothing, totals are 
preserved. 
Computing Estimates 
Standard errors may be calculated 
for medication estimates using any 
statistical software package, as long as 
clustering within facilities and other 
aspects of the complex sample design 
are taken into account. Software 
products such as SAS and STATA have 
these capabilities. Tables A, B, and C 
provide information to generate national PROC 
statement 
NEST 
statement 
ROC x File=y 
ESIGN=WOR; 
NEST RSTRATA 
FACNUM/ MISSUNIT; 
Design description in STATA 
Svyset [pw=SAMWT], strata (RSTRATA) psu (FACmedication estimates with the 2004 
NNHS data using the respective 
software packages. 
Searching for 
Information on 
Specific Medications 
Medication-specific information, 
such as drug characteristics and crude 
estimates of use by nursing home 
residents, is available at the NNHS 
website, http://www.cdc.gov/nchs/about/ 
major/nnhsd/drugdatabase.htm. This 
website has two PDF files—Drugs by 
NDC Class and Drug Estimates and 
Characteristics—with information on 
each medication collected in the 2004 
NNHS: unique drug names and codes, 
preliminary drug estimates, and drug 
characteristics. If an analyst wants to 
examine drug use by resident 
characteristics, he will need to access 
the PM PUF. The starting point for this 
type of analysis is the PDF files 
described in the following text to 
determine if there are enough cases of 
the medication (i.e., enough residents 
who took the medication of interest) to 
conduct meaningful analyses. 
PDF File 1: Drugs by NDC 
Class 
The Drugs by NDC Class file lists 
every medication in the NAMCS drug 
database by major therapeutic class code 
and therapeutic subclass code in 
ascending order. The 1995 National 
Drug Code Directory (see Appendix 
III), which was used to classify 
medications TOTCNT 
statement 
WEIGHT 
statement 
TOTCNT POPFAC 
NPOPRES; 
WEIGHT 
SAMWT; 
NUM) fpc(POPFAC) ll_n 
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Table C. Computations using SAS survey procedures 
File PROC STRATA CLUSTER WEIGHT 
Prescribed medications file . . . . . . .  
PROC SURVEY_ 
DATA=Y; STRATA RSTRATA; CLUSTER FACNUM; 
WEIGHT 
SAMWT; 
 
 
 reported in the 2004 NNHS, has 21 
major therapeutic classes and 139 
therapeutic subclasses. The major 
therapeutic class refers to the 21 broad 
categories in the NDC Directory that 
describes medications; each category 
generally includes the name of the body
organ it is indicated to treat. For 
example, the major therapeutic class 
central nervous system (NDC code 
0600) includes medications that treat 
disorders of the central nervous system. 
The therapeutic subclass further defines 
or describes the drug; for example, 
antidepressants (NDC code = 0630) is a
subcategory of the central nervous 
system and is indicated to treat 
depression. In the NAMCS Drug 
Database that was used to code 
medications collected in the 2004 
NNHS, most medications are assigned a
therapeutic subclass if it is known; if 
not, then it is defined by its major 
therapeutic class. 
The Drugs by NDC Class file 
provides a user-friendly format for data 
users to see which medications belong 
to each therapeutic class—major class 
and subclass—in the NAMCS Drug 
Database. The layout of this PDF file is 
as follows: 
Column 1: Major therapeutic class code 
Column 2: Therapeutic subclass code 
Column 3: Drug name code 
Column 4: Drug name 
In this PDF file, generally the major 
therapeutic class code is found at the 
top of the page unless otherwise 
indicated. 
PDF File 2: Drug 
Estimates and 
Characteristics 
All medications are identified by 
their unique five-digit drug name code only; no drug names are spelled out 
anywhere in the PM PUF. Therefore, if 
an analyst wants to find drug-specific 
information beyond unique drug name 
code and therapeutic class code, he can 
find the crude estimate for the number 
of residents who took a given 
medication, the rate of use per 10,000 
residents, and the drug characteristics 
associated with a given medication in 
the Drug Estimates and Characteristics 
file. This file contains the following 12 
columns: 
Column 1: Drug name 
Column 2: Drug name code 
Column 3: Drug estimate 
Column 4: Drug rate per 10,000 residents 
Column 5: Generic name 
Column 6: Generic name code 
Column 7: Rx status 
Column 8: DEA status 
Column 9: Comp status 
Column 10: Drug ingredients 
Column 11: Ingredient codes 
Column 12: Drug class codes 
Using the Edit-Find feature in this 
file, the data analyst can search for 
medications by name—brand or 
generic—to find the corresponding drug 
name codes and characteristics. First, 
enter the name of the medication in the 
Edit-Find box and click the Next key. If 
the drug name is in the Drug Estimates 
and Characteristics file, the drug name 
will be highlighted. This record will also 
have the five-digit drug name code, the 
weighted drug estimate, and the drug 
rate per 10,000 residents; the latter 
information will show if the medication 
was taken by any sampled residents in 
the NNHS. If these columns—drug 
estimate and drug rate per 10,000 
residents—are blank, then the medication was not taken by any 
sampled nursing home residents. If these 
columns are populated with numbers, 
then the drug name code should be 
noted, as it will be used to retrieve the 
residents’ records. 
The remainder of this section 
(Searching for Information on Specific 
Medications) illustrates how to use the 
two PDF files—Drugs by NDC Class 
and Drug Estimates and 
Characteristics—using antidepressants 
as an example. An analyst who wants to 
know which medications are classified 
as antidepressants, can perform the 
following steps: 
1.	 Go to Appendix III to find the major 
therapeutic class code and subclass 
code for antidepressants. The major 
therapeutic class code for 
antidepressants, a central nervous 
system drug, is 0600; the subclass 
code is 0630 (Figure 1). 
2.	 Go to the Drugs by NDC Class file 
and type 0600 in the Edit-Find box. 
Click Next or scroll through the 
document to find the page where 
0600 appears in the first column. 
3.	 Search for therapeutic subclass code 
0630 by using the Edit-Find feature 
or scrolling to the page where this 
code first appears. Therapeutic 
subclass code 0630 starts with the 
medication Sarafem on page 53 
(Figure 2). 
4.	 Antidepressants are listed through 
to page 55. There are a total of 85 
antidepressants listed in the Drugs 
by NDC Class file, complete with 
their unique drug name codes and 
drug names. 
Analysts may also want to focus on 
a particular type of antidepressant, such 
as serotonin-specific reuptake inhibitors 
(SSRIs). (SSRIs are a newer class of 
antidepressant medications that was 
introduced into the market in 1987 with 
fluoxetine (7). SSRIs block the reuptake 
of serotonin and have fewer side effects 
0628 96173 ZYPREXA 
0628 97002 OLANZAPINE 
0628 97168 SEROQUEL 
0628 98049 DONEPEZIL HCL 
0628 99101 QUETIAPINE FUMARATE 
0630 00318 SARAFEM 
0630 00510 ADAPIN 
0630 01009 LIMBITROL DS 10-25 
0630 01029 EFFEXOR XR 
0630 01064 WELLBUTRIN SR 
0630 01525 AMITRIL 
0630 01530 AMITRIPTYLINE 
0630 01535 AMITRIPTYLINE HCL W/PERPHENAZINE 
0630 01628 AMOXAPINE 
0630 02119 LEXAPRO 
0630 02256 ESCITALOPRAM OXALATE 
SOURCE: http://www.cdc.gov/nchs/data/nnhsd/DrugsbyNDCClass3.pdf. P 53. 
Figure 2. Drugs by National Drug Code Class file that shows where the listing of antidepressants begins 
1995 Version of the NDC Directory Used to Adjudicate 2004 NNHS Data 
0100 
0117 
0118 
0119 
0120 
0121 
0122 
0123 
0200 
0281 
0283 
0285 
0286 
0300 
0346 
0347 
0348 
0349 
ANESTHETIC DRUGS 
Anesthetics, Local (Injectable)
Anesthetics, General 
Adjuncts to Anesthesia/Analeptics
Medicinal Gases
Anesthetics, Topical
Anesthetics, Ophthalmic
Anesthetics, Rectal 
ANTIDOTES
Antidotes, Specific
Antidotes, General
Antitoxins/Antivenins 
Anaphylaxis Treatment Kit 
ANTIMICROBIAL AGENTS
Penicillins
Cephalosporins
Erythromycins/Lincosamides/Macrolides
Polymyxins 
0509 Relaxants/Stimulants, Urinary Tract 
0510 Calcium Channel Blockers 
0511 Carbonic Anhydrase Inhibitors
 0512 Beta Blockers 
0513 Alpha Agonist/Alpha Blockers
 0514 ACE Inhibitors 
0600 CENTRAL NERVOUS SYSTEM 
0626 Sedatives and Hypnotics
 0627 Antianxiety Agents
 0628 Antipsychotic/Antimanics
 0630 Antidepressants
 0631 Anorexiants/CNS Stimulants
 0632 CNS, Miscellaneous
 0633 Alzheimer-Type Dementia 
0634 Sleep Aid Products-OTC
 0635 Antiemetics 
0700 CONTRAST MEDIA/ 
RADIOPHARMACEUTICAL 
NOTE: NDC is the National Drug Code and NNHS is the National Nursing Home Survey. 
SOURCE: http://www.cdc.gov/nchs/data/nnhsd/Technicalnotes_April_6_2007_revision.pdf. 
Figure 1. 1995 National Drug Code Directory listing of therapeutic classes that were used to classify medications collected in the 2004 
National Nursing Home Survey 
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analyst who knows the names of 
particular SSRIs can identify the drug 
names among the list of antidepressants. 
After finding the drug name codes for 
the SSRIs (use the Drugs by NDC Class 
file and the Edit-Find function to locate 
the SSRI names), the analyst can check 
the Drug Estimates and Characteristics 
file to find out which SSRIs were taken 
by the sampled nursing home residents. 
The next example focuses on finding the 
antidepressant Lexapro in the two PDF 
files. The Drugs by NDC Class file 
shows that the drug name code for 
Lexapro is 02119 (Figure 3). 
If the analyst then goes to the Drug 
Estimates and Characteristics file and 
types in 02119 in the Edit-Find search 
feature, the medication will appear on 
page 111 in row 11 (Figure 4). This 
summary file allows analysts to obtain 
crude estimates of medication use and to 
easily identify drug characteristics without 
downloading and manipulating the PM 
PUF. 0628 
0628 
0628 
0628 
0628 
0630 
0630 
0630 
0630 
0630 
0630 
0630 
0630 
0630 
0630 
0630 
SOURCE: http://www.cdc.gov/nchs/data/nnhsd/DrugsbyNDCClas
Figure 3. Drugs by NDC Class file, highlightinLexapro was taken by an estimated 
300 residents and the rate per 10,000 
residents is 2. Additional information 
shows that the generic name for 
Lexapro is escitalopram oxalate; the 
generic name code for escitalopram 
oxalate is 70466. The Rx status field 
shows that Lexapro is a prescription 
medication, its DEA status is 
undetermined, and its composition status 
is single entity. If one scrolls across to 
the last field of the Lexapro record (not 
shown in Figure 4), the therapeutic class 
code shows that it is 0630, an 
antidepressant. 
Naming Conventions 
for Medication 
Variables 
Each medication reported in the PM 
PUF has 13 variables associated with it, 
which include codes for drug name, 96173 ZYPREXA 
97002 OLANZAPINE 
97168 SEROQUEL 
98049 DONEPEZIL HCL 
99101 QUETIAPINE FUMARATE 
00318 SARAFEM 
00510 ADAPIN 
01009 LIMBITROL DS 10-25 
01029 EFFEXOR XR 
01064 WELLBUTRIN SR 
01525 AMITRIL 
01530 AMITRIPTYLINE 
01535 AMITRIPTYLINE HCL W/PER
01628 AMOXAPINE 
02119 LEXAPRO 
02256 ESCITALOPRAM OXALATE 
s3.pdf. P 53. 
g listing of antidepressant Lexapro generic name, composition status, 
ingredients, DEA (or control) status, Rx 
(prescription) status, and therapeutic 
classes. As mentioned before, the large 
number of variables led to creating the 
PM PUF as a stand-alone file; the many 
variable names also resulted in 
developing a naming convention. The 
first medication in the file has the suffix 
‘‘01’’ or ‘‘1’’ to indicate that the variable 
refers to the first medication collected 
on each sampled resident (Table D). The 
second medication in the file has the 
suffix ‘‘02’’ or ‘‘2’’ to indicate that the 
variable refers to the second medication 
collected on the sampled residents. The 
remaining medications follow a similar 
pattern. Also, in the PM PUF data 
dictionary, the medications taken 
regularly but not on the day before the 
facility interview are referred to as 
‘‘Other medications.’’ The variables for 
these medications start with the letter 
‘‘O’’ for ‘‘Other’’ (Tables E). 
The variable labels listed in 
Tables D and E are provided to orient PHENAZINE 
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Rx DEA Comp
Status Status Statu
1 4 1
1 6 1
2 6 1 
2 6 1 
1 6 1
1 6 1
1 6 1 
1 6 1
1 6 1
2 6 1
1 7 1
1 6 1 
1 6 1
1 6 1
1 6 1 
1 6 1
2 6 1 
2 6 1
2 6 1
1 6 1
1 6 1 
1 6 1
1 6 1
e 
de 
15 
69
44 
87 
08
25
67 
80
97
30 
66
63 
20
07
03 
72 
75 
25 
40
20 
63 
10
43 
Nam
Co
701
539
703
704
500
555
509
531
542
506
704
561
523
700
518
529
538
524
520
535
561
549
512
ericGen
E ORID
 
 
E 
s
 
 
 
 
 
 
 
 
 
 
 
Drug Drug Rate 
Name Drug per 10,000 
Drug Name Code Estimate Residents Generic Name 
ZALEPLON 02107 304 0002 ZALEPLON 
NOROXIN 21385 304 0002 NORFLOXACIN 
BENADRYL ALLERGY 03332 303 0002 DIPHENHYDRAMINE HCL 
BILBERRY EXTRACT 02204 302 0002 BILBERRY EXTRACT 
SECTRAL 61330 302 0002 ACEBUTOLOL HYDROCHL
BLEPH-10 93030 300 0002 SULFACETAMIDE 
CEFUROXIME SODIUM 91070 300 0002 CEFUROXIME SODIUM 
ALMORA 01070 300 0002 MAGNESIUM GLUCONATE
PENTOXIL 04381 300 0002 PENTOXIFYLLINE 
BISAC-EVAC 04324 300 0002 BISACODYL 
LEXAPRO 02119 300 0002 ESCITALOPRAM OXALATE
COVERA HS 96131 300 0002 VERAPAMIL 
FML 00259 298 0002 FLUOROMETHOLONE 
OMNICEF 99014 298 0002 CEFDINIR 
CARTIA XT 00254 295 0002 DILTIAZEM 
KETOCONAZOLE 91085 295 0002 KETOCONAZOLE 
CLEAR EYES 06895 295 0002 NAPHAZOLINE 
POLYCOSE 24450 295 0002 GLUCOSE 
NEPHRON 00006 294 0002 EPINEPHRINE 
METHAZOLAMIDE 19025 294 0002 METHAZOLAMIDE 
ISOPTIN S.R. 91031 292 0002 VERAPAMIL 
PTU 41845 291 0002 PROPYLTHIOURACIL 
TEMOVATE 61440 290 0002 CLOBETASOL PROPIONAT
RCE: http://www.cdc.gov/nchs/data/nnhsd/Drugsestimatesandcharacteristics.pdf. P 111. 
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Figure 4. Drug estimates and characteristics file, highlighting listing of Lexapro 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
  
  
  
  
  
  
   
  
 
  
  
 
   
  the analyst to the PM PUF naming 
conventions; this is not the actual layout 
of the public-use file. The PM PUF file 
layout is found in the data dictionary at Table D. Variable naming convention for medica
Variable description 
Drug name code . . . . . . . . . . . . . . . . . . . . . . .  
Generic name code . . . . . . . . . . . . . . . . . . . . .  
Composition status code . . . . . . . . . . . . . . . . . .  
Prescription status code. . . . . . . . . . . . . . . . . . .  
Drug Enforcement Agency (DEA) code . . . . . . . . .  
Ingredient code 1 . . . . . . . . . . . . . . . . . . . . . . .  
Ingredient code 2 . . . . . . . . . . . . . . . . . . . . . . .  
Ingredient code 3 . . . . . . . . . . . . . . . . . . . . . . .  
Ingredient code 4 . . . . . . . . . . . . . . . . . . . . . . .  
Ingredient code 5 . . . . . . . . . . . . . . . . . . . . . . .  
Therapeutic class code 1 . . . . . . . . . . . . . . . . . .  
Therapeutic class code 2 . . . . . . . . . . . . . . . . . .  
Therapeutic class code 3 . . . . . . . . . . . . . . . . . .  http://www.cdc.gov/nchs/data/nnhsd/ 
March07_WebPMfiledatadictionary.pdf. 
The order of the medications in the PM 
PUF does not have any significance; it tions taken on the day before facility interview 
Medication num
1 2 
PMCODE01 
GEN01 
COMST01  
RXST01 
CONTR01 
RX1ING1  
RX1ING2  
RX1ING3  
RX1ING4  
RX1ING5  
DRG1CL1 
DRG1CL2 
DRG1CL3 
PMCODE02 
GEN02 
COMST02  
RXST02 
CONTR02 
RX2ING1  
RX2ING2  
RX2ING3  
RX2ING4  
RX2ING5  
DRG2CL1 
DRG2CL2 
DRG2CL3 reflects only how the nursing home 
respondent read the resident’s 
medication information from the 
medication administration record.(Medications 1–4) 
ber (variable labels) 
3 4 
PMCODE03 
GEN03 
COMST03  
RXST03 
CONTR03 
RX3ING1  
RX3ING2  
RX3ING3  
RX3ING4  
RX3ING5  
DRG3CL1 
DRG3CL2 
DRG3CL3 
PMCODE04 
GEN04 
COMST04  
RXST04 
CONTR04 
RX4ING1  
RX4ING2  
RX4ING3  
RX4ING4  
RX4ING5  
DRG4CL1 
DRG4CL2 
DRG4CL3 
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Table E. Variable naming convention for medications taken regularly but not on the day before facility interview (Medications 1–4) 
Medication number (variable labels) 
Variable description 1 2 3 4 
Drug name code . . . . . . . . . . . . . . . . . . . . . . .  OTHPMC01  OTHPMC02  OTHPMC03  OTHPMC04  
Generic name code . . . . . . . . . . . . . . . . . . . . .  OGEN01 OGEN02 OGEN03 OGEN04 
Composition status code . . . . . . . . . . . . . . . . . .  OCOMST01 OCOMST02 OCOMST03 OCOMST04 
Prescription status code. . . . . . . . . . . . . . . . . . .  ORXST01 ORXST02 ORXST03 ORXST04 
Drug Enforcement Agency (DEA) code . . . . . . . . .  OCONTR01 OCONTR02 OCONTR03 OCONTR04 
Ingredient code 1 . . . . . . . . . . . . . . . . . . . . . . .  OX1ING1  OX2ING1  OX3ING1  OX4ING1  
Ingredient code 2 . . . . . . . . . . . . . . . . . . . . . . .  OX1ING2  OX2ING2  OX3ING2  OX4ING2  
Ingredient code 3 . . . . . . . . . . . . . . . . . . . . . . .  OX1ING3  OX2ING3  OX3ING3  OX4ING3  
Ingredient code 4 . . . . . . . . . . . . . . . . . . . . . . .  OX1ING4  OX2ING4  OX3ING4  OX4ING4  
Ingredient code 5 . . . . . . . . . . . . . . . . . . . . . . .  OX1ING5  OX2ING5  OX3ING5  OX4ING5  
Therapeutic class code 1 . . . . . . . . . . . . . . . . . .  ODR1CL1 ODR2CL1 ODR3CL1 ODR4CL1 
Therapeutic class code 2 . . . . . . . . . . . . . . . . . .  ODR1CL2 ODR2CL2 ODR3CL2 ODR4CL2 
Therapeutic class code 3 . . . . . . . . . . . . . . . . . .  ODR1CL3 ODR2CL3 ODR3CL3 ODR4CL3 Analyzing the 
Prescribed 
Medications (PM) 
Data 
Many prescription medications (i.e., 
medications that require a doctor’s 
prescription in the noninstitutionalized 
setting) are available in either brand 
name or generic drug form. In order for 
an analyst to obtain an accurate estimate 
of medication use that considers both 
forms, NCHS advises analysts to search 
for medications by generic name code in 
the Drug Estimates and Characteristics 
file online. If a medication is a 
single-entity drug, the generic name will 
be in the generic name column with its 
generic name code in the next column. 
If a medication is a combination 
product, the generic name is 
‘‘combination product’’ (the generic 
name code for combination product is 
51380), but the ingredient field will list 
the generic name of interest; the 
corresponding generic name code will 
follow in the ingredient codes column. 
The ingredient code that one would find 
if a medication had a single-entity 
generic name should be the same as the 
generic name code found in the 
ingredient codes column. The drug 
fluoxetine (hydrochloride) illustrates this 
point in the following text. Fluoxetine 
belongs to a subcategory of 
antidepressants called selective serotonin 
reuptake inhibitors (SSRIs). Fluoxetine 
is the generic or chemical name for this SSRI, which helps improve a person’s 
mood. One of several brand names for 
this medication is Prozac. Using the 
Edit-Find feature in the Drug Estimates 
and Characteristics file to locate 
fluoxetine takes the analyst to page 98, 
where the record for Prozac is found 
(Figure 5). This record also shows that 
the generic name code for fluoxetine is 
80006. 
By clicking Next in the Edit-Find 
feature to find more fluoxetine­
containing medications, the analyst is 
taken to page 101, where fluoxetine is 
listed as a drug name (Figure 6). Here 
the generic name drug code is also 
80006 as found for Prozac. 
By clicking Next again, the analyst 
will arrive at Sarafem. This record on 
page 140 in the Drug Estimates and 
Characteristics file shows that 
fluoxetine is the generic name for 
Sarafem as well (Figure 7). 
By clicking Next again, the analyst 
will find that, on page 168, fluoxetine is 
one of the active ingredients in 
Symbyax (drug name code is 04043 
(Figure 8); cross-reference this drug 
name code in the Drugs by NDC Class 
file to check this drug name code). 
The search for fluoxetine leads the 
analyst to four different records within 
the Drug Estimates and Characteristics 
file. To generate a nationally 
representative estimate of all fluoxetine­
containing medications in the PM PUF, 
the SAS-callable SUDAAN program 
below is provided. This code will search 
the generic name code fields (GEN_ _ 
and OGEN_ _) and the ingredient code 
fields (RX_ ING_ and OX_ING_) for all medications that contain fluoxetine. 
This code will provide the count of 
unique nursing home residents who took 
one or more fluoxetine-containing 
medications; a resident can be counted 
only once even if he or she took more 
than one fluoxetine-containing 
medication. 
1.	 Using the generic name code for 
fluoxetine—80006—the SAS 
program in the following text will 
scan the generic name code fields 
and the ingredient code fields for 
medications taken the day before the 
facility interview and medications 
taken regularly but not on the day 
before the facility interview of each 
resident record to find fluoxetine 
hydrochloride. The resident records 
that contain at least one mention of 
fluoxetine will be flagged. 
Libname meds ’[filepath for PM 
PUF]’; 
data test; 
set meds; 
fluoxetine=0; 
array meds (240) GEN01– – 
GEN25 OGEN01– –OGEN15 
RX1ING1– –RX25ING1 
RX1ING2– –RX25ING2 
RX1ING3– –RX25ING3 
RX1ING4– –RX25ING4 
RX1ING5– –RX25ING5 
OX1ING1– –OX15ING1 
OX1ING2– –OX15ING2 
OX1ING3– –OX15ING3 
OX1ING4– –OX15ING4 
OX1ING5– –OX15ING5; 
do i=1 to 240; 
if meds (i)=80006 then 
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Drug Drug Rate Generic 
Name Drug per 10,000 Name Rx DEA Comp 
Drug Name Code  Estimate Residents Generic Name Code Status Status Status 
ACTONEL 00206 52014 0349 RISEDRONATE SODIUM 70168 1 6 1 
DULCOLAX 10575 51004 0342 BISACODYL 50630 2 6 1 
KCL 41850 49873 0334 POTASSIUM REPLACEMENT SOLUTIONS 54655 1 6 1 
GLUCOPHAGE 95111 48596 0326 METFORMIN 57192 1 6 1 
CELEXA 98115 45483 0305 CITALOPRAM HYDROBRIMIDE 59829 1 6 1 
CARDIZEM 05789 45193 0303 DILTIAZEM 51803 1 6 1 
FLOMAX 97126 44917 0301 TAMSULOSIN HYDROCHLORIDE 59731 1 6 1 
XALATAN 96167 44913 0301 LATANOPROST 59639 1 6 1 
MEGACE 18655 44810 0300 MEGESTROL 53295 1 6 1 
EFFEXOR 94070 44419 0298 VENLAFAXINE 57096 1 6 1 
PROZAC 25674 43293 0290 FLUOXETINE HYDROCHLORIDE 80006 1 6 1 
DETROL 98065 41794 0280 TOLTERODINE TARITRATE 59811 1 6 1 
DOCUSATE SODIUM 96027 38942 0261 DOCUSATE 51935 1 6 1 
DARVOCET-N 08470 38785 0260 COMBINATION PRODUCT 51380 1 4 2 
HYDROCHLOROTHIAZIDE 14930 38271 0256 HYDROCHLOROTHIAZIDE 52645 1 6 1 
FUROSEMIDE 13118 38243 0256 FUROSEMIDE 52385 1 6 1 
METAMUCIL 18930 37654 0252 PSYLLIUM 54965 2 6 1 
REMINYL 01141 36589 0245 GALANTAMINE HYDROBROMIDE 70296 1 6 1 
AMBIEN 93347 36554 0245 ZOLPIDEM TARTRATE 57048 1 4 1 
DITROPAN 09995 36232 0243 OXYBUTYNIN 54105 1 6 1 
ADVAIR DISKUS 01034 36095 0242 COMBINATION PRODUCT 51380 1 6 2 
XANAX 35023 36034 0241 ALPRAZOLAM 50113 1 4 1 
EXELON 00081 35773 0240 RIVASTIGMINE TARTRATE 70129 1 6 1 
VASOTEC 61565 35090 0235 ENALAPRIL 52028 1 6 1 
98 
SOURCE: http://www.cdc.gov/nchs/data/nnhsd/Drugsestimatesandcharacteristics.pdf. P 98. 
Figure 5. Drug estimates and characteristics file, highlighting listing of Prozac fluoxetine=1;
 
end;
 
keep resnum fluoxetine;
 
run;
 
2.	 This code will generate the 
frequency (n=461) of residents who 
took fluoxetine-containing 
medications and their resident IDs 
(Figure 9): 
Proc freq data=test;
 
tables resnum;
 
where fluoxetine=1;
 
run;
 
3.	 This code will link the file produced 
from the array in Step 1 with the 
resident file. In this step, the 
additional variables that the analyst 
wants included in the analytic file 
from the Current Resident Public-use 
File should be indicated in the 
programming code: 
Libname res ’[file path for Current 
Resident Public-use File]’; 
Proc sort data=test nodupkey; by resnum; run; 
Proc sort data=res.resident_ 
04nnhs_07192006b out=res; 
by resnum; run; 
data merged; 
merge test res(in=resident 
keep=resnum sex ageatint 
rstrata facnum popfac npopres 
samwt [and any other 
variables the analyst wants from 
the Current Resident Public-use 
File]); 
by resnum; 
if resident=1; run; 
4.	 Check the newly created analytic file 
to make sure that all the variables 
the analyst needs for his or her 
specific analysis are in the data set 
(in this analysis, nine variables were 
selected) (Figure 10). 
5.	 The following proc crosstab allows 
the analyst to obtain a more accurate 
weighted estimate for residents 
taking fluoxetine-containing 
medications (Figure 11). It is 
important to use the design variables and sample weight to generate 
precise estimates: 
Proc format; 
Value drgform 0=’No’ 1=’Yes’; 
run; 
Proc sort data=merged; by rstrata 
facnum; run; 
Proc crosstab data=merged 
design=wor; 
nest strata facnum/missunit; 
totcnt popfac npopres; 
weight samwt; 
class fluoxetine; 
table fluoxetine; 
rformat fluoxetine drgform.; run; 
6.	 This proc descript will allow the 
analyst to determine the weighted 
mean age at interview, by sex, of the 
residents reported to have taken 
fluoxetine-containing medications: 
Proc format;
 
Value sexform
 
1=’Males’
 
2=’Females’; run;
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Drug Drug Rate Generic
ame Rx DEA Comp 
Code Status Status Status 
6145 1 6 1
4094 1 2 1 
1380 1 6 2
3475 1 2 1
3700 1 6 1
0565 1 6 1 
7124 1 6 1
2975 2 6 1
7108 1 6 1
0642 1 6 1
4795 1 6 1
0006 1 6 1
0122 1 6 1
1382 2 6 2
6290 1 6 1
2490 1 6 1 
7220 1 6 1
0113 1 4 1
2885 2 6 1
2042 1 6 1
1380 1 6 2
3975 1 6 1
1978 1 2 1
0006 1 6 1
N
5
5
5
5
5
5
5
5
5
7
5
8
7
5
5
5
5
5
5
5
5
5
5
7
Name Drug per 10,000 
Drug Name Code Estimate Residents Generic Name 
DEPAKENE 08835 5133 0034 VALPROIC ACID 
OXYCODONE HCL 22303 5116 0034 OXYCODONE 
STROVITE 95062 5050 0034 COMBINATION PRODUCT 
METHADONE 18985 5001 0034 METHADONE  
FLAGYL 12585 5000 0034 METRONIDAZOLE 
BENZTROPINE MESYLATE 60180 4999 0034 BENZTROPINE 
PULMICORT 02279 4955 0033 BUDESONIDE  
LACT-AID 16925 4882 0033 LACTASE 
LESCOL 94154 4878 0033 FLUVASTATIN 
ZELNORM 02373 4873 0033 TEGASEROD MALEATE 
MYSOLINE 20135 4868 0033 PRIMIDONE 
FLUOXETINE 91079 4856 0033 FLUOXETINE HYDROCHLORIDE  
COMTAN 00054 4842 0032 ENTACAPONE 
CERTAGEN 04031 4775 0032 MULTIVITAMIN COMBINATION 
TERAZOSIN 94133 4759 0032 TERAZOSIN HCL 
HUMIBID LA 01026 4747 0032 GUAIFENESIN 
LAMICTAL 95181 4730 0032 LAMOTRIGINE 
ALPRAZOLAM 91062 4712 0032 ALPRAZOLAM  
HEMOCYTE 93074 4709 0032 IRON PREPARATIONS 
EPOGEN 93059 4586 0031 EPOETIN ALFA 
HYZAAR 95171 4516 0030 COMBINATION PRODUCT 
NORTRIPTYLINE 21403 4512 0030 NORTRIPTYLINE  
MARINOL 60870 4509 0030 DRONABINOL 
AZMACORT 02059 4401 0029 TRIAMCINOLONE ACETON 
101 
SOURCE: http://www.cdc.gov/nchs/data/nnhsd/Drugsestimatesandcharacteristics.pdf. P 101.
Figure 6. Drug estimates and characteristics file, highlighting listing of fluoxetine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
  
  Proc descript data=merged 
design=wor; 
nest strata facility/missunit; 
totcnt popfac npopres; 
weight samwt; 
class sex; 
subpopn fluoxetine=1; 
table sex; 
var ageatint; 
rformat sex sexform.; 
run; 
The output shows that the mean age 
of males who took fluoxetine-containing 
medications was 74 and the mean age of 
women who took fluoxetine-containing 
medications was 79 (Figure 12). 
A few medications in the Drug 
Estimates and Characteristics file may 
be incorrectly labeled as combination 
products (i.e., generic name 
code=51380) when, in fact, they are 
single-entity medications. If the analyst 
finds a medication that he or she knows 
is a single-entity medication but is 
labeled as a combination product (i.e., generic name code = 51380) in the 
Drug Estimates and Characteristics file, 
the analyst should use the Edit-Find 
feature to find its generic name and 
generic name code. 
Limitations to the PM 
Module and CAPI 
Instrument 
The CAPI instrument facilitated the 
collection of medication data in the 
2004 NNHS. Because the NNHS was 
designed to collect up to a total of 50 
medications names per resident, the 
survey required a system that facilitated 
quick data entry by interviewers. The 
drug lookup list reduced data entry time 
by allowing field interviewers to type in 
the first three letters of a medication 
name and automatically retrieve a list of 
medications beginning with those letters. Even with these features, there were 
some limitations to the PM module and 
the CAPI system. The wording of the 
two questions that ask for medication 
names was somewhat complex. The 
drug list was not exhaustive; therefore, 
many drugs had to be entered manually 
into the ‘‘Other, specify’’ field. This also 
increased the number of misspelled 
medications and the editing time 
required to correct them post-data 
collection. The survey did not 
specifically ask if the resident received a 
brand name medication or a generic 
medication. It is possible that the 
resident could have taken the generic 
form of a medication but the respondent 
found it easier to report the brand name 
(i.e., Prozac instead of fluoxetine 
hydrochloride). Finally, the system did 
not include a lookup list for the medical 
conditions collected for the ‘‘Reason 
why prescribed’’ item. 
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140
 Drug Drug Rate Generic 
Name Drug per 10,000 Name Rx DEA Comp 
Drug Name Code Estimate Residents Generic Name Code Status Status Status 
ULCEREASE 00279 COMBINATION PRODUCT 51380 2 6 2 
ACETANILID 00285 ACETANILID 50015 1 6 1 
ACETATED RINGER'S 00290 COMBINATION PRODUCT 51380 1 6 2 
ZICAM 00303 ZINCUM GLUCONICUM 70198 2 6 1 
AMINO-MAG 00309 MAGNESIUM GLYCINATE 70199 2 6 1 
DILATING DROPS 00314 UNDETERMINED 50000 1 6 3 
SARAFEM 00318 FLUOXETINE HYDROCHLORIDE 80006 1 6 1 
ACHROMYCIN 00340 TETRACYCLINE 55725 1 6 1 
ACID-EZE 00370 UNDETERMINED 50000 3 7 3 
ACIDULATED PHOSPHATE FLUORIDE 00380 FLUORIDE 52318 1 6 1 
ACNE 00395 UNDETERMINED 50000 3 7 3 
ACNOMEAD 00420 UNDETERMINED 50000 3 7 3 
ACTH 00455 CORTICOTROPIN 51400 1 6 1 
ACTIDIL 00470 TRIPROLIDINE 56020 2 6 1 
ACTIFED WITH CODEINE 00481 COMBINATION PRODUCT 51380 1 5 2 
ACTOL 00485 COMBINATION PRODUCT 51380 2 6 2 
ADENOSINE 00535 ADENOSINE 50080 1 6 1 
ADRENAL CORTEX 00555 HYDROCORTISONE 52655 1 6 1 
ADRENERGIC AGENT 00563 UNDETERMINED 50000 3 7 3 
ADSORBONAC 00590 SODIUM CHLORIDE 55315 2 6 1 
AEROSEB-DEX 00610 DEXAMETHASONE 51635 1 6 1 
AFKO-LUBE SYRUP 00640 DOCUSATE 51935 2 6 1 
AHF 00668 ANTIHEMOPHILIC FACTOR HUMAN 50320 1 6 1 
AKNE DRYING LOTION 00690 COMBINATION PRODUCT 51380 2 6 2 
SOURCE: http://www.cdc.gov/nchs/data/nnhsd/Drugsestimatesandcharacteristics.pdf. P 140. 
Figure 7. Drug estimates and characteristics file, highlighting listing of Sarafem Summary and 
Suggestions for Future 
Data Collection 
Collecting medication data on 
nursing home residents is increasingly 
important. The majority of nursing home 
residents are elderly and frail and 
require numerous medications. The 2004 
NNHS provided valuable lessons on 
collecting medication data that can 
enhance future surveys. Suggestions for 
future surveys include: 
+	 Simplifying the medication 
questions. +	 Adding a question about whether the 
medication taken by the resident 
was a brand name or generic drug. 
+	 Adding a question about the 
documentation on the reason that 
medications were prescribed. 
+	 Providing a lookup list of medical 
conditions that facilitates data entry 
for why the medications were 
prescribed. 
Knowledge about medications taken 
by nursing home residents is useful to 
the long-term care community, which is 
striving to find ways to ensure quality 
care while containing costs. Medication 
data on other long-term care populations 
will be available through NCHS in the 
future; the 2007 National Home and Hospice Care Survey collected 
medication information, which will add 
to our current understanding of 
pharmacotherapy in long-term care 
settings. 
Additional information about the 
2004 NNHS and the data collected is 
available from the NNHS website: 
http://www.cdc.gov/nchs/nnhs.htm. 
Public-use data files are available for 
download from the website. Questions 
about these data can be directed to the 
NCHS Office of Information Services, 
Information Dissemination Staff at 
1–800–232–4363 or at cdcinfo@cdc.gov, 
or to the Long-term Care Statistics 
Branch at 301–458–4747. 
Drug Drug Rate Generic 
Name Drug per 10,000 Name Rx DEA Comp 
Code Estimate Residents Generic Name Code Status Status Status Drug Ingredients 
12665 4751 0032 FLUDROCORTISONE ACETATE 52295 1 6 1 
02223 4467 0030 EZETIMIBE 70494 1 6 1 
03177 3148 0021 CALCIUM CARBONATE 50785 2 6 1 
41860 2748 0018 FOLIC ACID 52355 3 6 1 
92120 2494 0017 DOXAZOSIN MESYLATE 51953 1 6 1 
21144 2162 0014 NITROGLYCERIN 53945 1 6 1 
93204 1788 0012 SELEGILINE 56630 1 6 1 
22630 1624 0011 PANCRELIPASE 54165 1 6 1 
97159 1089 0007 CALCITRIOL 59736 1 6 1 
20095 989 0007 SIMETHICONE 55240 2 6 1 
95149 883 0006 COMBINATION PRODUCT 51380 1 6 2 PIPERACILLIN SODIUM, TAZOBACTAM SODIUM 
30781 790 0005 COMBINATION PRODUCT 51380 1 6 2 ATENOLOL, CHLORTHALIDONE 
31775 600 0004 TOLAZAMIDE 55870 1 6 1 
04043 516 0003 COMBINATION PRODUCT 51380 1 6 2 OLANZAPINE, FLUOXETINE HYDROCHLORIDE 
00096 494 0003 COMBINATION PRODUCT 51380 2 6 2 CHONDROITIN SULFATE, GLUCOSAMINE 
12035 414 0003 COMBINATION PRODUCT 51380 2 6 2 UNDETERMINED, ACETAMINOPHEN 
11688 393 0003 COMBINATION PRODUCT 51380 1 6 2 ACETAMINOPHEN, BUTALBITAL, CAFFEINE 
99155 355 0002 LEVOCARNITINE 57049 2 6 1 
07740 312 0002 BISACODYL 50630 2 6 1 
93360 276 0002 ENOXACIN 56720 1 6 1 
92050 268 0002 POTASSIUM REPLACEMENT SOLUTIONS 54655 1 6 1 
02382 241 0002 DOXYCYCLINE HYCLATE 70655 1 6 1 
02148 220 0001 DICLOFENAC SODIUM 80004 1 6 1 
95101 200 0001 SALICYLIC ACID 55160 2 6 1 
168 
SOURCE: http://www.cdc.gov/nchs/data/nnhsd/Drugsestimatesandcharacteristics.pdf. P 168.
Figure 8. Drug estimates and characteristics file, highlighting listing of Symbyax 
The FREQ Procedure 
Cumulative Cumulative 
RESNUM Frequency Percent  frequency percent 
111006 1 0.22 442 95.88 
111102 1 0.22 443 96.10 
111206 1 0.22 444 96.31 
111509 1 0.22 445 96.53 
111707 1 0.22 446 96.75 
111807 1 0.22 447 96.96 
111904 1 0.22 448 97.18 
112208 1 0.22 449 97.40 
112210 1 0.22 450 97.61 
112401 1 0.22 451 97.83 
112911 1 0.22 452 98.05 
113006 1 0.22 453 98.26 
113309 1 0.22 454 98.48 
113701 1 0.22 455 98.70 
113802 1 0.22 456 98.92 
113809 1 0.22 457 99.13 
113912 1 0.22 458 99.35 
114305 1 0.22 459 99.57 
114306 1 0.22 460 99.78 
115008 1 0.22 461 100.00 
NOTES: FREQ refers to frequency.  RESNUM is the resident identification number. 
SOURCE: Generated by author for this report. 
Figure 9. SAS output of resident identification numbers of those who took fluoxetine­
containing medications generated from Step 2 
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PUF resident id Fluoxetine FACNUM SEX Age at interview RSTRATA POPFAC NPOPRES SAMWT 
1204 0 12 2 91 17 372 -1 23 
1205 1 12 2 80 17 372 -1 23 
1206 0 12 1 86 17 372 -1 23 
1207 0 12 1 41 17 372 -1 23 
1208 0 12 2 77 17 372 -1 23 
1209 0 12 2 86 17 372 -1 23 
1210 0 12 2 72 17 372 -1 23 
1211 0 12 1 85 17 372 -1 23 
1212 0 12 2 86 17 372 -1 23 
1301 0 13 2 96 14 639 -1 85 
1302 0 13 2 92 14 639 -1 85 
1303 0 13 1 88 14 639 -1 85 
1304 0 13 2 90 14 639 -1 85 
1305 0 13 2 91 14 639 -1 85 
1306 0 13 1 84 14 639 -1 85 
1307 1 13 2 88 14 639 -1 85 
1308 0 13 2 87 14 639 -1 85 
1309 0 13 2 90 14 639 -1 85 
1310 0 13 1 84 14 639 -1 85 
1311 0 13 2 90 14 639 -1 85 
1312 0 13 1 77 14 639 -1 85 
1401 0 14 2 95 1 1201 -1 53
NOTES: PUF resident id is the resident ID in the Public-use File.  FACNUM is the facility identification number. RSTRATA, POPFAC, and NPOPRES are sample design variables needed to generate 

accurate national estimates. SAMWT is the weight for resident estimates.
 
SOURCE: Generated by author for this report.
 
Figure 10. Temporary SAS dataset created from merging the dataset from Step 1 with the Current Resident Public-use File 
2884.27 
The CROSSTAB Procedure 
Variance Estimation Method: Taylor Series (WOR)
by: FLUOXETINE. 
FLUOXETINE
 Total No Yes
4Sample Size 13507 13046 
Weighted Size 1492207.00 1443542.00 
SE Weighted 11281.95 11308.30 
Row Percent 100.00 96.74 
SE Row Percent 0.00 0.19 
Lower 95% Limit
 ROWPER 96.34 2.90 
Upper 95% Limit
ROWPER 97.10 3.66 
Col Percent 100.00 96.74 3.26 
SE Col Percent 0.00 0.19 0.19 
Lower 95% Limit
 COLPER 96.34 2.90 
Upper 95% Limit
COLPER 97.10 3.66 
Tot Percent 100.00 96.74 3.26 
SE Tot Percent 0.00 0.19 0.19 
Lower 95% Limit
 TOTPER 96.34 2.90 
Upper 95% Limit
TOTPER 97.10 3.66
61 
48665.00 
3.26 
0.1 
SOURCE: Generated by author for this report. 
Figure 11. SAS output of PROC CROSSTAB of residents by fluoxetine-containing 
medication status (yes/no) generated from Step 5 
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Research Triangle Institute
The DESCRIPT Procedure 
Variance Estimation Method: Taylor Series (WOR)
For Subpopulation: FLUOXETINE = 1
by: Variable, SEX.
Variable 
Sex 
Total 
Age at
Interview 
Sample Size
Weighted Size 
Total 
Lower 95% Limit
 Total 
Upper 95% Limit
Total 
Mean 
 SE Mean 
Lower 95% Limit 
Mean 
Upper 95% Limit
Mean 
461 
48665.00 
3798370.00 
3336043.76 
4260696.24 
78.05 
0.88 
76.33 
79.77 
Males 
115 
12304.00 
908630.00 
690459.74 
0.941.85 
3277703.011126800.26 
73.85 79.47
70.22 
77.48 
Females 
346 
36361.00
2889740.00 
2501776.99 
77.64 
81.31 
SOURCE: Generated by author for this report. 
Figure 12. SAS output of PROC DESCRIPT of residents who took fluoxetine-containing 
medications by sex, generated from Step 6 
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List of Prescribed Medications (PM) Module Items 
PMPRE. 
THIS IS THE FIRST PAGE OF THE PRESCRIBED MEDICATIONS (PM) SECTION. STATUS = {STATUS}.
 
IF THIS SECTION HAS ALREADY BEEN COMPLETED, RETURN TO THE CHOOSE PERSON SCREEN.
 
PRESS 1 AND ENTER TO CONTINUE.
 
IF RECORDS FOR THIS PERSON ARE NOT AVAILABLE (RP), PRESS 2 AND ENTER.
 
IF CONSENT REQUIRED AND NOT OBTAINED FOR THIS PERSON (CP), PRESS 3 AND ENTER.
 
PM1A. 
{Please give me the names of all the medications {SP} received yesterday, that is, from 12:01 AM to 12:00 
midnight {DATE BEF CURRENT INTERVIEW}. Please include all the standing or routine medications, or PRN 
medications.} 
{Any other medications?} 
{TYPE THE FIRST 3 LETTERS OF THE MEDICATION. THEN USE ARROW KEYS TO LOCATE 
MEDICATIONS, AND PRESS ENTER TO SELECT. IF NO MEDICATIONS TAKEN, ENTER AAA. IF 
MEDICATION IS NOT LISTED, ENTER ZZZ.} 
{ENTER 999 TO LEAVE ROSTER.} 
MEDICATION MEDICATION (OTHER) REASON PRESCRIBED 
PM [1–25] PM OS [1–25] WhyPM[1–25] 
PM1B. 
SPECIFY MEDICATION. 
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Why was this medication prescribed for {SP}?
 
ENTER REASON.
 
PM2. 
Does {SP} receive any medications on a regularly scheduled basis that were not administered yesterday? 
Please include only medications with standing orders for administration. Please do not include PRN medications. 
PRESS F1 FOR HELP SCREEN. 
YES  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1  
NO  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2  
DK 
RF 
PM2A. 
{Please give me the names of all of these medications.} 
{Any other medications?} 
{TYPE THE FIRST 3 LETTERS OF THE MEDICATION. THEN USE ARROW KEYS TO LOCATE 
MEDICATIONS, AND PRESS ENTER TO SELECT. IF MEDICATION IS NOT LISTED, ENTER ZZZ.} 
{ENTER 999 TO LEAVE ROSTER.} 
MEDICATION MEDICATION (OTHER) REASON PRESCRIBED 
OthrPM [1–15] OthrPMOS [1–15] WhyOthPM[1–15] 
PM2B. 
SPECIFY MEDICATION. 
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Why was this medication prescribed for {SP}?
 
ENTER REASON(S).
 
PM3. 
{Since admission {FAD}/During the past 30 days, that is, since {PAST 30 DAYS}, did {SP} have any type of 
reaction to a drug or medication?} 
PRESS F1 FOR HELP SCREEN. 
YES  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1  
NO  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2  
DK 
RF 
PM3A. 
{Please give me the names of all the drugs or medications to which {SP} had a reaction.} 
{Any other medications?} 
{TYPE THE FIRST 3 LETTERS OF THE MEDICATION. THEN USE ARROW KEYS TO LOCATE 
MEDICATIONS, AND PRESS ENTER TO SELECT. IF MEDICATION IS NOT LISTED, ENTER ZZZ.} 
{ENTER 999 TO LEAVE ROSTER.} 
MEDICATION MEDICATION (OTHER) REACTION 
Drug Name[1–5] Drug Name OS[1–5] Reaction[1–5] 
PM3B. 
SPECIFY MEDICATION. 
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What kind of reaction did {SP} have?
 
ENTER REACTION.
 
PMEND. 
YOU HAVE COMPLETED PM FOR {SP}. PRESS 1 AND ENTER TO CONTINUE. 
PMNAV. 
YOU HAVE COMPLETED THE PM SECTION FOR {SP}. YOUR OPTIONS ARE TO: 
CONTINUE WITH PA {STATUS} FOR {SP} . . . . . . . . . . . . . . . . . . . . . . . . . 1 
  
CHOOSE A DIFFERENT SECTION FOR {SP} . . . . . . . . . . . . . . . . . . . . . 2 
  
CHOOSE A DIFFERENT PERSON . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 
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PM2 
The following are types of medications to include: Vitamin B-12, bisphosphonates (alendronate and risedrontate), 
Lupron depot, depo provera, methotrexate. 
PM3 
A drug reaction includes any unexpected, unintended, undesired, or excessive response to a medication that 
c Requires discontinuing the medicine (therapeutic or diagnostic) 
c Requires changing the medication therapy 
c Requires modifying the dose (except for minor dosage adjustments) 
c Necessitates admission to a hospital (e.g., an ED visit) 
c Prolongs stay in a health care facility 
c Necessitates supportive treatment 
c Significantly complicates diagnosis 
c Negatively affects prognosis 
c Results in temporary permanent harm, disability, or death 
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Summary of Key Items for Data Collection 
Facility Visit Activities 
Approximately 40 minutes of the administrator’s (or designee) time will be needed to answer questions about the facility, 
residents, and staff. Access to the following information will expedite the interview. 
¶ Current number of residents with Medicare, Medicaid, and private pay as primary source of payment 
¶ Payment rates for Medicaid and private pay residents 
¶ Medicare and Medicaid facility ID numbers 
¶ Number of admissions and discharges for 2003 
¶ List of all current residents on the rolls of this facility as of midnight 
[INSERT DATE BEFORE THE DATE OF INTERVIEW IN BOLD PRINT] 
Sampled Current Residents Information 
The study collects information about the sampled current residents and discharges primarily from the person’s medical record. 
Approximately 25 minutes per resident is required to collect the following information: 
¶ Health status information from the Minimum Data Set (MDS) assessments 
¶ Medications administered the day before interview date 
¶ Hospital or emergency room visits during residency 
¶ Vaccination/immunization status 
¶ Expenditure information including: total charges, sources of payment, and amount paid by resident/discharge for all care 
during the first month/billing period and the most recent or final month/billing period 
To collect this medical and billing information, we will need to work with staff familiar with the medical and billing records. 
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1995 Version of the NDC Directory Used to Adjudicate 2004 NNHS Data 
0100 ANESTHETIC DRUGS 0600 CENTRAL NERVOUS SYSTEM 
0117 Anesthetics, Local (Injectable) 0626 Sedatives and Hypnotics 
0118 Anesthetics, General 0627 Antianxiety Agents 
0119 Adjuncts to Anesthesia/Analeptics 0628 Antipsychotic/Antimanics 
0120 Medicinal Gases 0630 Antidepressants 
0121 Anesthetics, Topical 0631 Anorexiants/CNS Stimulants 
0122 Anesthetics, Ophthalmic 0632 CNS, Miscellaneous 
0123 Anesthetics, Rectal 0633 Alzheimer-type Dementia 
0200 
0281 
ANTIDOTES 
Antidotes, Specific 
0634 
0635 
Sleep Aid Products–OTC 
Antiemetics 
0283 Antidotes, General 0700 CONTRAST MEDIA/ 
0285 Antitoxins/Antivenins RADIOPHARMACEUTICAL 
0286 Anaphylaxis Treatment Kit 0789 Diagnostics, Radiopaque & Nonradioactive 
0300 
0346 
0347 
ANTIMICROBIAL AGENTS 
Penicillins 
Cephalosporins 
0790 
0791 
0792 
Diagnostics–Radiopharmaceuticals 
Therapeutics–Radiopharmaceuticals 
Miscellaneous 
0348 Erythromycins/Lincosamides/Macrolides 0800 GASTROINTESTINAL AGENTS 
0349 Polymyxins 0874 Disorders, Acid/Peptic 
0350 Tetracyclines 0875 Antidiarrheals 
0351 Chloramphenicol/Derivatives 0876 Laxatives 
0352 Aminoglycosides 0877 Miscellaneous Gastrointestinals 
0353 Sulfonamides and Trimethoprim 0878 Antispasmodics/Anticholinergics 
0354 Urinary Tract Antiseptics 0879 Antacids 
0355 
0356 
0357 
0358 
0388 
Miscellaneous Antibacterial Agents 
Antimycobacterial/Anti-leprosy Agents 
Quinolones/Derivatives 
Antifungals 
Antiviral Agents 
0900 
0912 
0913 
0914 
0915 
METABOLIC/NUTRIENTS 
Hyperlipidemia 
Vitamins/Minerals 
Nutrition, Enteral/Parenteral 
Repl/Regs of Electrolytes/Water Balance 
0400 HEMATOLOGIC AGENTS 0916 Calcium Metabolism 
0408 Deficiency Anemias 0917 Hematopoietic Growth Factor 
0409 
0410 
0411 
Anticoagulants/Thrombolytics 
Blood Components/Substitutes 
Hemostatics/Antihemophilics 
1000 
1032 
1033 
HORMONES/HORMONAL MECHANISMS 
Adrenal Corticosteroids 
Androgens/Anabolic Steroids 
0500 CARDIOVASCULAR-RENAL DRUGS 1034 Estrogens/Progestins 
0501 Cardiac Glycosides 1035 Anterior Pituitary/Hypothalamic Function 
0502 Antiarrhythmic Agents 1036 Blood Glucose Regulators 
0503 Antianginal Agents 1037 Thyroid/Antithyroid 
0504 Vascular Disorders, Cerebral/Peripheral 1038 Antidiuretics 
0505 Agents Used to Treat Shock/Hypotension 1039 Relaxants/Stimulants, Uterine 
0506 Antihypertensive Agents 1040 Contraceptives 
0507 Diuretics 1041 Infertility 
0508 Coronary Vasodilators 1042 Growth Hormone Secretion Disorder 
0509 
0510 
0511 
0512 
0513 
0514 
Relaxants/Stimulants, Urinary Tract 
Calcium Channel Blockers 
Carbonic Anhydrase Inhibitors 
Beta Blockers 
Alpha Agonist/Alpha Blockers 
ACE Inhibitors 
1100 
1180 
1181 
1182 
1183 
IMMUNOLOGICS 
Vaccines/Antisera 
Immunomodulators 
Allergenic extracts 
Immune serums 
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1264 Antiseptics/Disinfectants 1720 Analgesics/General 
1265 Dermatologics, Misc. 1721 Analgesics, Narcotic 
1266 Keratolytics 1722 Analgesics, Non-narcotic 
1267 Antiperspirants 1723 Antimigraine/Other Headaches 
1268 Topical Steroids 1724 Antiarthritics 
1269 Burn/Sunburn, Sunscreen/Suntan Products 1725 Antigout 
1270 Acne Products 1726 Central Pain Syndrome 
1271 Topical Anti-infectives 1727 NSAID 
1272 Anorectal Products 1728 Antipyretics 
1273 Personal Care (Vaginal) Products 1729 Menstrual Products 
1274 
1275 
Dermatitis/Antipuretics 
Topical Analgesics 1800 1860 
ANTIPARASITICS 
Antiprotozoals 
1300 NEUROLOGIC DRUGS 1862 Anthelmintics 
1371 Extrapyramidal Movement Disorders 1863 Scabicides/Pediculicides 
1372 Myasthenia Gravis 1864 Antimalarials 
1373 
1374 
Skeletal Muscle Hyperactivity 
Anticonvulsants 1900 1940 
RESPIRATORY TRACT 
Antiasthmatics/Bronchodilators 
1400 ONCOLYTICS 1941 Nasal Decongestants 
1479 Antineoplastics, Miscellaneous 1943 Antitussives/Expectorants/Mucolytics 
1480 Hormonal/Biological Response Mod. 1944 Antihistamines 
1481 Antimetabolites 1945 Cold Remedies 
1482 Antibiotics, Alkaloids, Enzymes 1946 Lozenge Products 
1483 DNA Damaging Drugs 1947 Corticosteroid-inhalation, Nasal 
1500 OPHTHALMICS 2000 UNCLASSIFIED/MISCELLANEOUS 
1566 Glaucoma 2087 Unclassified 
1567 Cycloplegics/Mydriatics 2095 Pharmaceutical Aids 
1568 Ocular Anti-infective/Anti-inflammatory 2096 Surgical Aids 
1569 Miscellaneous Ophthalmics 2097 Dental Preparation 
1570 Decongestants/Antiallergy Agents 2098 Dentrifice/Denture Products 
1571 Contact Lens Products 2099 Mouth Pain, Cold Sore, Canker 
1600 OTOLOGICS 2100 HOMEOPATHIC PRODUCTS 
1670 Otic, Topical (Misc) 
1671 Vertigo/Motion Sickness/Vomiting 
NOTE: NDC is the National Drug Code and NNHS is the National Nursing Home Survey. 
Vital and Health Statistics 
series descriptions 
SERIES 1.	 Programs and Collection Procedures—These reports 
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